The global breast cancer screening tests market is projected to experience tremendous growth, reaching an estimated value of US$ 4.4 billion by 2033, according to a recent market analysis. This significant increase from US$ 1.9 billion in 2022 highlights the growing importance of early detection and innovation in diagnostic technologies.
This segment, expected to grow at a CAGR of nearly 7.8% over the next decade, encompasses various imaging techniques such as mammography. The development of more precise technologies has demonstrably contributed to minimizing the disease burden of breast cancer.
Heightened awareness also plays a crucial role. Breast cancer remains one of the most prevalent cancers among women. To combat this, numerous organizations, including the FDA with its Pink Ribbon Sunday Mammography Awareness Program, have launched vital initiatives to educate women about the importance of regular screenings.
Imaging Tests Lead the Charge
The report indicates that imaging tests currently hold the dominant position within the breast cancer screening market, capturing over 54.3% of the total value share in 2022. This segment is anticipated to maintain its lead, with a projected Compound Annual Growth Rate (CAGR) of close to 7.8% throughout the forecast period (2023-2033).
Awareness Programs Play a Vital Role
The rising prevalence of breast cancer, one of the most common cancers among women, underscores the critical role of breast cancer awareness initiatives. Numerous organizations, including the FDA with its Pink Ribbon Sunday Mammography Awareness Program, have championed these efforts in raising public awareness and encouraging regular screenings.
This market expansion signifies a positive step towards a future where early detection of breast cancer becomes even more prevalent. With advancements in diagnostic tools and continued emphasis on screening programs, the fight against breast cancer continues to gain momentum.
Drivers and Challenges have an Impact on Market Dynamics, which can Impact Businesses. Find more Insights in a Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-17758
The rising breast imaging markets, increasing government and private investments to support the increasing demand for breast imaging, and a better reimbursement picture is likely to provide breast imaging market participants with a wide variety of breast imaging market key trends and opportunities prospects.
The National Cancer Institute conducts and encourages the development of recommendations for different organisations. Breast cancer is one of the most common causes of mortality among women.
As mammography is the standard procedure for screening breast cancer, governments and other healthcare organisations all over the world are taking steps to ensure that women have access to mammography screening. The global demand for breast imaging and mammography is expanding as a result.
There have been a lot of developments in the area that reduce over-diagnosis and improve sensitivity to identify tiny carcinomas. These ongoing improvements in this discipline are projected to boost the global breast imaging market‘s mammography segment.
The development and increased usage of improved mammography machines with novel technology are fueling breast imaging market future trends.
The Asia Pacific area is a prominent revenue generator in the breast imaging market. The rising prevalence of breast cancer, rising healthcare expenditure, an increase in the number of breast cancer awareness programs, and high government spending on breast cancer research studies in several Asia Pacific countries are the major factors driving the Asia Pacific breast imaging market opportunities.
KEY TAKEAWAYS:
- In the United States, the breast imaging market is estimated to reach US$ 3.1 Billion by 2032, increasing at a CAGR of 6.9% through 2032.
- The breast imaging market in the United Kingdom is expected to be worth US$ 350.3 Million by 2032, with a CAGR of 5.9% through 2032.
- China’s breast imaging market is expected to reach US$ 613.6 Million by 2032, with a CAGR of 6.4% through 2032.
- The market for breast imaging in Japan is expected to be valued at US$ 494.9 Million by 2032, expanding at a 5.4% annual rate through 2032.
- South Korea is expected to reach a market size of US$ 308.8 Million in breast imaging by 2032, with a CAGR of 5.0% through 2032.
- The breast imaging market’s ionizing breast imaging segment from the technology category is predicted to develop at a CAGR of 7.0% through 2032.
- By 2032, the hospitals & clinics sector in the breast imaging market’s end-user category will grow at a CAGR of 7.0%.
COMPETITIVE LANDSCAPE:
New market research report on Breast Imaging says that Hologic, Inc., GE Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Fujifilm Holdings Corporation, Canon Inc., Aurora Healthcare US Corp., Allengers, Dilon Technologies, Inc., Planmed Oy, Delphinus Medical Technologies, Inc., Micrima Limited, CMR Naviscan Corporation, SuperSonic Imagine, and Carestream Health., are among the legacy players vendors.
The research offers a comprehensive competition analysis of these top competitors in the breast imaging market, including breast imaging market growth, breast imaging market share, breast imaging market adoption trends and important market strategies.
Recent Development in the Breast Imaging:
- Densitas Inc. announced collaboration with Mammography Educators, LLC in November 2020 to build an artificial intelligence-powered telehealth technologist training platform that would promote business continuity in mammography clinics.
- Hologic, Inc. announced the commercial availability of 3DQuorum Imaging Technology powered by Genius AI in Europe in October 2020. According to the company’s disclosures, the 3DQuorum Imaging Technology uses Genius AI-powered analytics to reconstruct high-resolution 3D data. This technology aids in lowering picture interpretation time.
Key Segments
By Diagnostics Test Type:
- Blood Marker Tests
- Imaging TestMammography
MRI screening test
Molecular Breast Imaging Test
PET scan
Ultrasound
- Genetic TestFluorescence In Situ Hybridization
HER gene test
- Immunohistochemistry Test
By End User:
- Hospitals
- Diagnostic Centres
- Cancer Institutes
- Research Laboratories
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa